<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2025//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_250101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Curated"><PMID Version="1">39840881</PMID><DateCompleted><Year>2025</Year><Month>01</Month><Day>22</Day></DateCompleted><DateRevised><Year>2025</Year><Month>06</Month><Day>04</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">2038-1840</ISSN><JournalIssue CitedMedium="Internet"><Volume>116</Volume><Issue>1</Issue><PubDate><Year>2025</Year><Month>Jan</Month></PubDate></JournalIssue><Title>Recenti progressi in medicina</Title><ISOAbbreviation>Recenti Prog Med</ISOAbbreviation></Journal><ArticleTitle>[CAR-T therapy in elderly patients with relapsed/refractory diffuse large B-cell lymphoma. Clinical case of the San Martino Hospital in Genoa].</ArticleTitle><Pagination><StartPage>12e</StartPage><EndPage>14e</EndPage><MedlinePgn>12e-14e</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1701/4416.44127</ELocationID><Abstract><AbstractText>CAR-T therapy (chimeric antigen receptor T-cell) has revolutionized the prognosis of patients with diffuse large B-cell lymphoma (DLBCL) that have relapsed or are refractory to conventional chemotherapies. In particular, patients who have relapsed or are refractory to two lines of therapy are patients who have a poor prognosis. The advent of CAR-T immunotherapy is an innovative approach with which we can give hope of recovery even in the case of refractory disease, even for patients who are not candidates for high-dose therapies, for example due to age. Here we present a clinical case of a 74-year-old patient at second relapse, refractory to two lines of chemotherapy and subjected to third-line CAR-T with axicabtagene ciloleucel, after a good response to bridge therapy with rituximab polatuzumab and bendamustine (RPB). Complete remission of the disease still persists eleven months after treatment. Tolerance to CAR-T was excellent, with grade 1 cytokine release syndrome (CRS), no neurological complications (ICANS-immune effector cell-associated neurotoxicity syndrome) and no infectious complications. Severe hypogammaglobulinemia persists eleven months after CAR-T reinfusion, for which he still performs immunoglobulin replenishment for prophylactic purposes.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Ghiggi</LastName><ForeName>Chiara</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Divisione di Ematologia e terapie cellulari, Irccs Ospedale Policlinico San Martino, Genova.</Affiliation></AffiliationInfo></Author></AuthorList><Language>ita</Language><PublicationTypeList><PublicationType UI="D002363">Case Reports</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D004740">English Abstract</PublicationType></PublicationTypeList><VernacularTitle>La terapia CAR-T nel paziente anziano con linfoma B diffuso a grandi cellule ricaduto/refrattario. Caso clinico dell&#x2019;Ospedale Policlinico San Martino di Genova.</VernacularTitle></Article><MedlineJournalInfo><Country>Italy</Country><MedlineTA>Recenti Prog Med</MedlineTA><NlmUniqueID>0401271</NlmUniqueID><ISSNLinking>0034-1193</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>U2I8T43Y7R</RegistryNumber><NameOfSubstance UI="C000629083">axicabtagene ciloleucel</NameOfSubstance></Chemical><Chemical><RegistryNumber>4F4X42SYQ6</RegistryNumber><NameOfSubstance UI="D000069283">Rituximab</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D018941">Antigens, CD19</NameOfSubstance></Chemical><Chemical><RegistryNumber>981Y8SX18M</RegistryNumber><NameOfSubstance UI="D000069461">Bendamustine Hydrochloride</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D001688">Biological Products</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016403" MajorTopicYN="Y">Lymphoma, Large B-Cell, Diffuse</DescriptorName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016219" MajorTopicYN="Y">Immunotherapy, Adoptive</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012008" MajorTopicYN="N">Recurrence</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000971" MajorTopicYN="N">Antineoplastic Combined Chemotherapy Protocols</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000069283" MajorTopicYN="N">Rituximab</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018941" MajorTopicYN="N">Antigens, CD19</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000069461" MajorTopicYN="N">Bendamustine Hydrochloride</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001688" MajorTopicYN="N">Biological Products</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009364" MajorTopicYN="N">Neoplasm Recurrence, Local</DescriptorName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>1</Month><Day>22</Day><Hour>12</Hour><Minute>29</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>1</Month><Day>22</Day><Hour>12</Hour><Minute>28</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>1</Month><Day>22</Day><Hour>8</Hour><Minute>12</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39840881</ArticleId><ArticleId IdType="doi">10.1701/4416.44127</ArticleId></ArticleIdList></PubmedData></PubmedArticle></PubmedArticleSet>